Lisata Therapeutics and WARPNINE Reports Initial Results from P-Ib/IIa (iLSTA) trial of Certepetide Regimen in Pancreatic Ductal Adenocarcinoma (PDAC)
Shots:
- P-Ib/IIa (iLSTA) trial assessed certepetide (LSTA1; iRGD cyclic peptide) ± SoC CT ± Imfinzi in LA inoperable PDAC pts (N=30) randomized into 3 arms, with A1 (n=5) receiving SoC CT + PBO Imfinzi & PBO certepetide; A2 (n=5) receiving SoC CT + certepetide & PBO Imfinzi; A3 (n=20) receiving SoC CT + Imfinzi & certepetide
- Initial data (from 16 RECIST evaluable pts) was presented at ASCO GI 2025, showed 5 PRs (4 from A3) after 2 cycles of therapy & 11 SDs
- After 4 cycles, the study depicted 9 PRs (8 from A3), 1 CR (A2) & 6 SDs, >90% CA19-9 level reduction in 6 pts (5 from A3) & >50% CA19-9 level reduction in 8 pts (6 from A3). 5 pts had a significant immune cell infiltration (4 from A3)
Ref: Lisata Therapeutics | Image: Lisata Therapeutics & WARPNINE
Related News:- Lisata Therapeutics Collaborates with Kuva Labs to Advance Non-Invasive, High-Precision Cancer Diagnostics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
